Wall Street Zen upgraded shares of Inventiva (NASDAQ:IVA – Free Report) from a sell rating to a hold rating in a report released on Saturday morning,Wall Street Zen reports.
A number of other equities research analysts have also commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald began coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Guggenheim upped their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Truist Financial increased their price target on shares of Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research note on Friday. Finally, Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $15.86.
Check Out Our Latest Analysis on IVA
Inventiva Price Performance
Inventiva (NASDAQ:IVA – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The firm had revenue of $0.75 million during the quarter. On average, equities analysts expect that Inventiva will post -0.81 earnings per share for the current fiscal year.
Institutional Trading of Inventiva
Several institutional investors and hedge funds have recently added to or reduced their stakes in IVA. Engineers Gate Manager LP lifted its position in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after purchasing an additional 43,280 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Inventiva during the 4th quarter worth approximately $603,000. Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva during the 1st quarter worth approximately $1,111,000. Eventide Asset Management LLC acquired a new stake in shares of Inventiva during the 4th quarter worth approximately $1,155,000. Finally, Propel Bio Management LLC bought a new stake in shares of Inventiva during the fourth quarter worth approximately $4,650,000. 19.06% of the stock is owned by institutional investors.
About Inventiva
Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.
Inventiva’s lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.
Further Reading
- Five stocks we like better than Inventiva
- Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
